

References

I-194

1. Muntoni F, Frank D, Sardone V, et al. Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression in Duchenne Muscular Dystrophy patients with mutations amenable to exon 53 skipping (S22.001). *Neuro.* 2018;90(15 Supplement).
2. Institute for Clinical and Economic Review. Deflazacort, eteplirsen, and golodirsen for Duchenne Muscular Dystrophy: effectiveness and value. Final report. August 15, 2019.
3. Hayes, Inc. Hayes Emerging Technology Report. Vyondys (Golodirsen) for Duchenne Muscular Dystrophy. Lansdale, PA: Hayes, Inc.; December 2019.
4. Golodirsen In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 26, 2021.
5. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Golodirsen.
6. Micromedex DrugDex Compendium®. 2023. Golodirsen.
7. Vyondys 53TM (golodirsen) injection, for intravenous use [package insert]. Cambridge, MA. Sarepta Therapeutics, Inc. Revised 2/2021.